Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Donostia / San Sebastian – page 13

210 clinical trials in Donostia / San Sebastian, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Donostia / San Sebastian at a glance
210
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

210 trials in Donostia / San Sebastian

Open in trial search

Gastric cancer

Not recruiting

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Bladder cancer

Not recruiting

Study of Sacituzumab Govitecan, Zimberelimab, and Domvanalimab for Patients with Muscle Invasive Bladder Cancer Ineligible for Cisplatin Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Fundacion Para El Progreso De La Oncologia En Cantabria

Hepatocellular carcinoma

Not recruiting

Study of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dementia Alzheimer's type

Not recruiting

Study on the Effectiveness and Safety of GSK4527226 in Patients with Early Alzheimer's Disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Glaxosmithkline Research & Development Limited

Malignant melanoma

Not recruiting

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Cervix carcinoma

Not recruiting

Study of Dostarlimab for Patients with High-Risk Locally Advanced Cervical Cancer After Chemo-Radiation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Non-small cell lung cancer stage III

Not recruiting

Study on Osimertinib and Drug Combination for Adults with Unresectable Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Prodromal Alzheimer's disease

Not recruiting

Study of RO7269162 in people at risk for or with early-stage Alzheimer's Disease: Effects on brain amyloid buildup

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Breast cancer metastatic

Not recruiting

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:F. Hoffmann-La Roche AG

Triple negative breast cancer

Not recruiting

Study of Nadunolimab with Gemcitabine and Carboplatin for Patients with Advanced Triple Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Cantargia AB

Malignant melanoma+1

Not recruiting

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Donostia / San Sebastian

What the registry says about research in the country

01 Neurodegenerative Diseases

Groundbreaking research focusing on Parkinson's disease and Alzheimer's disease, including studies of novel therapeutics and disease-modifying treatments.

  • LRRK2-driven Parkinson's treatment evaluation
  • Early-stage Alzheimer's interventions
  • Down syndrome-associated Alzheimer's research

Multiple trials investigating innovative approaches to manage disease progression and symptoms.

02 Oncology Studies

Comprehensive research into various cancer types, with emphasis on advanced colorectal cancer and melanoma treatments.

  • Targeted therapies for pancreatic adenocarcinoma
  • Brain metastases in melanoma patients
  • Innovative combinations for lymphomas

Focus on personalized treatment approaches and novel drug combinations.

03 Rare Diseases

Specialized research targeting Amyotrophic Lateral Sclerosis (ALS) and other rare conditions, exploring innovative therapeutic approaches.

  • Combined therapy approaches for ALS
  • Soft tissue sarcoma treatments
  • Ocular Myasthenia Gravis studies

Development of targeted therapies for challenging medical conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.